Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19
Genre
Journal articleDate
2020-11-18Author
Kuo, Tsun-YungLin, Meei-Yun
Coffman, Robert L.
Campbell, John D.
Traquina, Paula
Lin, Yi-Jiun
Liu, Luke Tzu-Chi
Cheng, Jinyi
Wu, Yu-Chi
Wu, Chung-Chin
Tang, Wei-Hsuan
Huang, Chung-Guei
Tsao, Kuo-Chien
Chen, Charles
Permanent link to this record
http://hdl.handle.net/20.500.12613/6227
Metadata
Show full item recordDOI
https://doi.org/10.1038/s41598-020-77077-zAbstract
The COVID-19 pandemic is a worldwide health emergency which calls for an unprecedented race for vaccines and treatment. In developing a COVID-19 vaccine, we applied technology previously used for MERS-CoV to produce a prefusion-stabilized SARS-CoV-2 spike protein, S-2P. To enhance immunogenicity and mitigate the potential vaccine-induced immunopathology, CpG 1018, a Th1-biasing synthetic toll-like receptor 9 (TLR9) agonist was selected as an adjuvant candidate. S-2P in combination with CpG 1018 and aluminum hydroxide (alum) was found to be the most potent immunogen and induced high titer of neutralizing antibodies in sera of immunized mice against pseudotyped lentivirus reporter or live wild-type SARS-CoV-2. In addition, the antibodies elicited were able to cross-neutralize pseudovirus containing the spike protein of the D614G variant, indicating the potential for broad spectrum protection. A marked Th1 dominant response was noted from cytokines secreted by splenocytes of mice immunized with CpG 1018 and alum. No vaccine-related serious adverse effects were found in the dose-ranging study in rats administered single- or two-dose regimens of S-2P combined with CpG 1018 alone or CpG 1018 with alum. These data support continued development of CHO-derived S-2P formulated with CpG 1018 and alum as a candidate vaccine to prevent COVID-19 disease.Citation
Kuo, TY., Lin, MY., Coffman, R.L. et al. Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19. Sci Rep 10, 20085 (2020). https://doi.org/10.1038/s41598-020-77077-zCitation to related work
Springer Science and Business Media LLCHas part
Scientific Reports, Vol. 10ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.eduae974a485f413a2113503eed53cd6c53
http://dx.doi.org/10.34944/dspace/6209